Moderna has a lot of trials going on and may have a lot of potential sources of revenue in the future. But treasury yields are tanking this isn’t a stock I’d buy today as there isn’t anything terribly exciting in its pipeline outside of its personalized cancer vaccine. But flu vaccines, COVID shots, and RSV vaccines may not be enough to make the business profitable in the long run. But if you’re ready to hold on for a few more years, it could turn out to be a wise move. (And buying the stock now, on the dip, could be a smart move too.) Moderna has five respiratory vaccines that have generated positive phase 3 data, and five non-respiratory candidates involved in pivotal studies. So there’s reason to be optimistic about the company’s product approval forecasts, and therefore its revenue potential down the road.
Recent News: MRNA
Please bear with us as we address this and restore your personalized lists. I became a self-made millionaire by the age of 21, trading thousands of Penny Stocks – yep you read best tech stocks to buy in q2 2021 that right, Penny Stocks. Despite setbacks, key valuation metrics shed light on Moderna’s enduring market impact. With assets exceeding $15.8B against liabilities of roughly $3.88B, Moderna displays robust financial strength, characterized by ratios that underscore a robust current and quick ratio, indicating strong liquidity reserves.
- The company will develop updated versions as the virus continues to change over time.
- These studies show the wide variance of the available data on day trading profitability.
- (And buying the stock now, on the dip, could be a smart move too.) Moderna has five respiratory vaccines that have generated positive phase 3 data, and five non-respiratory candidates involved in pivotal studies.
- The market can be unpredictable, and emotions often get in the way of making sound decisions.
- The company has experienced rapid growth due to its innovative mRNA technologies, especially as the U.S. authorized the COVID-19 vaccine developed by Moderna Inc. for human use in December 2020.
First, let’s consider all of the important points Moderna talked about during its annual R&D day — and why it’s making certain decisions. Lowering its R&D expenses and slashing certain programs will result in fewer products launched in the next few years. This is after — just last year — forecasting the launch of as many as 15 new products over the next five years. © 2024 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.
Financial Performance
In the meantime, the company is also working on developing other products, such as mRNA-3927, which is a treatment for propionic acidemia (an organic acid disorder). Its most promising product may be the personalized cancer vaccine it is working on with Merck, which is currently in phase 3 trials. It could potentially treat multiple cancers, including non-small cell lung cancer, melanoma, and other types of tumors. Moderna is projecting $4 billion in revenue this year, which factors in approval of its respiratory syncytial virus (RSV) vaccine, which the company anticipates should come within the first half of the year. The company is still working on a combination shot for COVID and the flu, which looks to still be part of its long-term strategy. If Moderna can replicate its COVID-19 success with other respiratory viruses like the flu and RSV, there’s a case to be made that shareholders will be rewarded over time.
As Moderna brings more products to the market, there will be additional opportunities to add to the position over time. Moderna approaches the development of vaccines and therapeutics using Messenger RNA (mRNA) technology. Put very simply, a vaccine utilizing mRNA technology teaches the body to make its own medicine.
MRNA Competitors
Expanding beyond COVID is going to be key to Moderna stock being a good long-term investment. The company does have products in its pipeline that could be blockbusters, including its RSV vaccine (peak sales of up to $2.1 billion) and its vaccine for the cytomegalovirus (potentially $5 billion at its peak). But it will take years for sales from those products, assuming they obtain approval, to flow through to the business. Moderna (MRNA 7.48%) was a top stock to own during the early stages of the pandemic. The COVID-19 vaccine maker reached a market cap of nearly $200 billion at its peak in 2021. But nowadays, with revenue from its vaccine diminishing and no longer being a strong growth catalyst, investors have become bearish on the healthcare stock.
analyst rating
If you’ve held Moderna shares for a while, could lock in a profit if you sold, and are looking to move on to other opportunities, you might consider at least trimming your position. Moderna (MRNA) reported better third-quarter results than expected Thursday morning, as the vaccine maker reported a surprise profit for the period amid its efforts to cut costs. In the 2024 presidential election’s latest impact on the stock markets, shares of several vaccine makers were down Friday morning following the nomination of Robert F. Kennedy Jr. to head the Departme… Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company’s peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure.
You can find a company’s peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis. Short interest is important to track because it can a beginners guide to cosmos act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish. Crucially, Moderna’s reaffirmed focus on groundbreaking research and strategic endeavors, like the RSV vaccine expansion, predicates a future less reliant on pandemic-driven sales and more diversified across therapeutic developments and territories. Moreover, if confirmed, Kennedy’s stance and policies could exacerbate existing vaccine hesitancy, impacting both current and future vaccine uptake in the U.S.